CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 43 enrolled
Drug / intervention
dalfampridine ER +1 moredrug
Likely dose
dalfampridine ER 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01356940
NCT01356940Phase 4Completed
CompareCT.gov

A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis

Brown, Theodore R., M.D., MPH·interventional·Posted May 20, 2011·Updated Oct 31, 2018

In Brief

A Phase 4 clinical trial evaluating dalfampridine ER and placebo for Multiple Sclerosis. Completed, enrolled 43 participants across 1 site.

Detailed Summary

A randomized placebo controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with multiple sclerosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsAcorda Therapeutics

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2011
Enrollment StartNov 1, 2010
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.1 years ago

Interventions

dalfampridine ERdrug

dalfampridine ER 10mg bid for 4 weeks

placebodrug

identical placebo tablet administered bid for four weeks